Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots

  • Arbutus Biopharma Corporation ABUS and its licensee Genevant Sciences have sued Pfizer Inc PFE and its partner BioNTech SE BNTX in the U.S. District Court for the District of New Jersey, seeking damages for infringement of five U.S. patents.
  • Arbutus and Genevant Sciences seek compensation for the unlicensed use of patented lipid nanoparticle (LNP) delivery technologies in Pfizer/BioNTech's famed COVID-19 vaccine.
  • The lawsuit by Arbutus and Genevant says Pfizer/BioNTech engaged in licensing discussions for the technology, but they did not "result in a settlement."
  • Arbutus Biopharma sued Moderna Inc MRNA in the Delaware court for infringing six patents in manufacturing and selling MRNA-1273, Moderna's vaccine for COVID-19.
  • In their lawsuit against Moderna, Arbutus said they were not looking to block the company from selling, manufacturing, or distributing MRNA-1273 but seek fair compensation.
  • Moderna sued Pfizer and BioNTech for patent infringement filed between 2010 and 2016 covering foundational mRNA technology.
  • Last year in March, Alnylam Pharmaceuticals Inc ALNY filed separate lawsuits in the Delaware federal court against Pfizer and Moderna, seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines.
  • Price Action: ABUS shares are down 1.80% at $3.01 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsPenny StocksHealth CareSmall CapLegalGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!